AUPH News and Press, Aurinia Pharmaceuticals Inc From 05/04/23

2023-05-04 13:08:04 ET Start Time: 08:30 End Time: 09:27 Aurinia Pharmaceuticals Inc. (AUPH) Q1 2023 Earnings Conference Call May 04, 2023, 08:30 AM ET Company Participants Peter Greenleaf - President and CEO Joe Miller - CFO Jamie Harrell - Head of IR ...

2023-05-04 07:48:27 ET Aurinia Pharmaceuticals ( NASDAQ: AUPH ) shares spiked in the pre-market Thursday after the Canadian biotech posted a strong revenue beat with its Q1 2023 financials and increased its outlook for 2023 amid a strong uptake for its lupus nephritis therapy Lupkyn...

2023-05-04 06:03:45 ET Aurinia Pharma press release ( NASDAQ: AUPH ): Q1 GAAP EPS of -$0.18 beats by $0.04 . Revenue of $34.41M (+59.1% Y/Y) beats by $6.29M . As of March 31, 2023, Aurinia had cash, cash equivalents and restricted cash and short-term investment...

$34.4 million in net revenue for the first quarter of 2023; an increase of 59% over the first quarter of the prior year Increases 2023 revenue guidance range to $135 - $155 million from net product sales of LUPKYNIS Significant progress across Commercial, R&D and Intellectual ...

2023-05-03 15:01:12 ET Aurinia Pharma ( NASDAQ: AUPH ) is scheduled to announce Q1 earnings results on Thursday, May 4th, before market open. The consensus EPS Estimate is -$0.22 and the consensus Revenue Estimate is $28.12M (+30.0% Y/Y). Over the last 3 months, EPS es...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the National Institute for Health and Care Excellence (NICE) has recommended LUPKYNIS ® (voclosporin) as an option for treating adults with active lupus nephritis (LN) class III, IV or V (including ...

2023-05-03 03:10:35 ET Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021 the Company introduced the first FDA-approved oral therapy...

Both leading independent proxy advisors recommend shareholders vote for the re-election of incumbent directors, equity incentive plan amendment, and appointment of auditors Company reminds shareholders to vote today to protect the value of their investment and ensure Aurinia’s cont...

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization of LUPKYNIS ® (voclosporin) in combination with a background immunosuppressive therapy to treat adults with...

Leading independent proxy advisor also recommends shareholders vote for say-on-pay, equity incentive plan amendment, and appointment of auditors Company reminds shareholders to vote today to protect the value of their investment and ensure Aurinia’s continued momentum Share...